Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that Thijs Spoor, the Company’s Chief Executive Officer, will present at the 42^nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Thursday, January 11, 2024, at 12 p.m. PT. Management will also participate at investor conferences alongside the J.P. Morgan Healthcare Conference in San Francisco.

42^nd Annual J.P. Morgan Healthcare Conference – Company Presentation
Date: Thursday, January 11, 2024
Time: 12 p.m. PT
Location: The Westin St. Francis Hotel, San Francisco, CA (Elizabethan B)

7th Annual BFC Global HealthCare BD & Investment Conference – Panel, “Great Science, Great Challenges: Partnership with the Big Pharma”
Moderator: Thijs Spoor
Panelists: Executives from Novartis, Sanofi, Bayer, Johnson and Johnson Innovative Medicine, and AstraZeneca China
Date: Sunday, January 7, 2024
Time: 9:15 a.m. PT
Location: The St. Regis, San Francisco, CA

7th Annual BFC Global HealthCare BD & Investment Conference – Roadshow
Date: Sunday, January 7, 2024
Time: 2:30 p.m. PT
Location: The St. Regis, San Francisco, CA (Room 2)

Biotech Showcase – Company Presentation
Date: Monday, January 8, 2024
Time: 10:30 a.m. PT
Location: Hilton San Francisco - Union Square, Yosemite A (Ballroom Level)

BIO Partnering @ JPM 2024
Date: January 8 - 12, 2024
Location: Marriott Marquis, San Francisco, CA

About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.